Health Evolution Features COTA’s Advancements With RWE & COVID-19

Along with COTA’s data analytics expertise, Hackensack Meridian Health has been pioneering some of the early work to understand COVID-19. Stuart Goldberg, MD, chief of the Division of Outcomes and Value Research at the John Theurer Cancer Center and Mike Doyle, CEO of COTA, recently spoke with Health Evolution about the findings so far, and how we continue to learn from existing patients.

COTA Supports FDA Assessment of Real-World Data through Membership in COVID-19 Evidence Accelerator

Leveraging its past knowledge of real-world evidence applications and learnings, COTA has joined the COVID-19 Evidence Accelerator program, a joint initiative of Friends of Cancer Research (Friends) and the Reagan-Udall Foundation for the Food and Drug Administration. Through this initiative, COTA is delivering findings from its observational, real-world studies using data from over 3,000 patients hospitalized with COVID-19 within the Hackensack Meridian Health network.

COTA, Inc. Announces Participation in the 2020 American Society of Clinical Oncology (ASCO) Virtual Scientific Program and DIA 2020 Virtual Global Annual Meeting

COTA, Inc., is pleased to announce its involvement and participation in two industry leading conferences – the 2020 American Society of Clinical Oncology (ASCO) Virtual Scientific Program and the DIA 2020 Virtual Global Annual Meeting. Collectively, the involvement at these two premier events further underscores the importance of RWD’s role in clinical research and oncology care delivery.

Subscribe for Updates

Receive our latest news and research from thought leaders in the RWD industry
  • This field is for validation purposes and should be left unchanged.